herenciageneticayenfermedad: Parkinson's Disease

viernes, 24 de noviembre de 2017

Parkinson's Disease - Nov 23, 2017 Edition

	November 23, 2017
	Parkinson's Disease
	The latest Parkinson's disease news from News Medical

	Parkinson's disease will soon become looming pandemic, research reveals New research shows that the number of people with Parkinson's disease will soon grow to pandemic proportions. In a commentary appearing today in the journal JAMA Neurology, University of Rochester Medical Center neurologist Ray Dorsey, M.D. and Bastiaan Bloem, M.D., Ph.D., with Radboud University Medical Center in the Netherlands, argue that the medical community must be mobilized to respond to this impending public health threat.

	Study points at lysosomal storage disorder genes as potential key contributors to Parkinson's An international study has shed new light on the genetic factors associated with Parkinson's disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder. The study appears in the journal Brain.

New study shows how SNO reaction may contribute to Parkinson's disease

A new study from The Scripps Research Institute is the first to show precisely how a process in nerve cells called the S-nitrosylation (SNO) reaction- which can be caused by aging, pesticides and pollution- may contribute to Parkinson's disease.

	Scientists develop novel mouse model to capture pathology of sporadic ALS and FTD Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and death of nerve cells, which leads to problems with movement or mental functioning. Examples include Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

	Nanowires could be potential drug delivery tools for neurodegenerative diseases Millions of Americans suffer from neurodegenerative diseases such as Alzheimer's and Parkinson's. Researchers have identified promising new treatments, such as cerebrolysin, but current clinical approaches are ineffective because critical concentrations of the drug dissipate within the body before reaching the blood-brain barrier and central nervous system.